| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Revenue | 12.5 | 5 | ||
| Selling, general and administrative | 27.596 | 12.796 | ||
| Research and development | 3.791 | 9.061 | ||
| Total operating expenses | 31.387 | 21.857 | ||
| Loss from operations | -18.887 | -16.857 | ||
| Other (expense) income | -0.014 | 0.199 | ||
| Interest income | 2.201 | 2.246 | ||
| Total other income, net | 2.187 | 2.445 | ||
| Net loss before income taxes | -16.7 | -14.412 | ||
| Income tax expense | 0 | 0.5 | ||
| Net loss | -16.7 | -14.912 | ||
| Unrealized gain on marketable securities | 0.189 | -0.085 | ||
| Comprehensive loss | -16.511 | -14.997 | ||
| Net loss per share - basic (in dollars per share) | -0.59 | -0.53 | ||
| Net loss per share - diluted (in dollars per share) | -0.59 | -0.53 | ||
| Weighted-average common shares outstanding, basic (in shares) | 28,540,519 | 28,079,071 | ||
| Weighted-average common shares outstanding, diluted (in shares) | 28,540,519 | 28,079,071 | ||
LENZ Therapeutics, Inc. (LENZ)
LENZ Therapeutics, Inc. (LENZ)